Prosecution Insights
Browse Companies Examiners Firms Draft Your Response
Office Actions › Ideaya Biosciences Inc. › 17420833
Last updated: October 25, 2026
Application No. 17/420,833

TREATMENT OF CANCER HAVING GNAQ OR GNA11 GENETIC MUTATIONS WITH PROTEIN KINASE C INHIBITORS

Non-Final OA
Filed
Jul 06, 2021
Priority
Jan 07, 2019 — provisional 62/789,177 +2 more
Examiner
YOO, SUN JAE
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Ideaya Biosciences Inc.
OA Round
3 (Non-Final)
71%
Grant Probability
Favorable
3-4
OA Rounds
0m
Est. Remaining
72%
With Interview

Interview Optional

— +0.3% interview lift. Interview already conducted in this application's prosecution history. This examiner has a 71% grant rate with +0.3% interview lift. Since an interview has already been tried, recommend written response with narrowed claims based on precedent claim evolution patterns.
Based on 1241 resolved cases, 2023–2026

Examiner Intelligence

YOO, SUN JAE View full profile →
Grants 71% — above average
71%
Career Allowance Rate
883 granted / 1241 resolved
+11.2% vs TC avg
Minimal +0% lift
Without
With
+0.3%
Interview Lift
resolved cases with interview
Typical timeline
2y 8m
Avg Prosecution
95 currently pending
Career history
1320
Total Applications
across all art units

Statute-Specific Performance

§101
1.1%
-38.9% vs TC avg
§103
17.0%
-23.0% vs TC avg
§102
27.7%
-12.3% vs TC avg
§112
33.9%
-6.1% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1241 resolved cases

Prosecution Timeline

Show 11 earlier events
Jan 21, 2026
Examiner Interview Summary
Jan 21, 2026
Applicant Interview (Telephonic)
Feb 02, 2026
Response after Non-Final Action
Mar 19, 2026
Applicant Interview (Telephonic)
Mar 19, 2026
Examiner Interview Summary
Jul 14, 2026
Non-Final Rejection mailed
Oct 19, 2026
Applicant Interview (Telephonic)
Oct 19, 2026
Examiner Interview Summary

Precedent Cases

Applications granted by this same examiner with similar technology

18/709,657
Patent 12767631
METHOD FOR PRODUCING POLYETHER NITRILE
2y 5m to grant Granted Oct 20, 2026
17/598,660
Patent 12746246
COMPOSITIONS AND METHODS FOR TREATING AGE-RELATED MACULAR DEGENERATION
5y 0m to grant Granted Sep 29, 2026
18/620,225
Patent 12735424
FUSED PYRAZINE DERIVATIVES AS A2A / A2B INHIBITORS
2y 5m to grant Granted Sep 15, 2026
17/423,422
Patent 12692253
Antimicrobial Compounds and Methods
5y 0m to grant Granted Jul 28, 2026
18/289,449
Patent 12690381
ORGANOMETALLIC COMPOUND AND APPLICATION THEREOF
2y 8m to grant Granted Jul 21, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

3-4
Expected OA Rounds
71%
Grant Probability
72%
With Interview (+0.3%)
2y 8m (~0m remaining)
Median Time to Grant
High
PTA Risk
Based on 1241 resolved cases by this examiner. Grant probability derived from career allowance rate.

Ready to respond to this office action?

IP Author drafts your complete OA response — amendments, arguments, and claim strategy — in minutes, not days.

Start Drafting Your Response →

Data sourced from USPTO Patent File Wrapper (daily) and Office Action Archive (weekly). Analysis generated by IP Author.

Data: USPTO Patent File Wrapper (daily) • Office Action Archive (weekly) • 89M+ prosecution events

© 2026 IP Author — Browse Office Actions • Examiners • Companies • Firms

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month